Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$7.90
-3.1%
$8.38
$5.01
$10.75
$10.11M0.88170,891 shs3,146 shs
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
$0.37
$0.31
$0.19
$1.41
$6.05M2.12725,886 shs54,897 shs
Sernova Corp. stock logo
SEOVF
Sernova
$0.32
+3.2%
$0.40
$0.29
$0.83
$96.64M1.1619,347 shs14,800 shs
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$1.05
+1.9%
$1.70
$0.94
$9.38
$483K11.03 million shs200,128 shs
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$6.02
+0.2%
$10.50
$0.29
$3.72
$255.66M3.931.22 million shs912,164 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
+3.16%+1.24%-9.55%+42.98%+35.83%
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
-6.22%+5.37%+15.59%+7.29%-72.98%
Sernova Corp. stock logo
SEOVF
Sernova
-2.63%-6.05%-24.70%-35.13%-47.36%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
-3.74%+4.04%-38.69%-44.02%-79.10%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.00%-1.06%+12.08%+47.63%-39.33%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Sernova Corp. stock logo
SEOVF
Sernova
2.3365 of 5 stars
3.05.00.00.02.80.00.0
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
2.00
HoldN/AN/A
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
N/AN/AN/AN/A
Sernova Corp. stock logo
SEOVF
Sernova
2.00
Hold$1.50370.96% Upside
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/A

Current Analyst Ratings

Latest SXTC, UMRX, GHSI, SEOVF, and KZIA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2024
Sernova Corp. stock logo
SEOVF
Sernova
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$1.50
2/2/2024
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.83$0.14 per share57.36$6.39 per share1.24
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
$20K302.29N/AN/A$0.50 per share0.74
Sernova Corp. stock logo
SEOVF
Sernova
N/AN/AN/AN/A$0.03 per shareN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$1.97M0.25N/AN/A$32.12 per share0.03
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$22.50M11.36N/AN/A$1.04 per share5.79

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$0.1171.82N/A0.51%2.01%1.21%5/20/2024 (Estimated)
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
-$13.78MN/A0.00N/AN/AN/AN/AN/AN/A
Sernova Corp. stock logo
SEOVF
Sernova
-$28.91M-$0.09N/AN/AN/A-226.64%-145.26%6/12/2024 (Estimated)
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
-$5.93MN/A0.00N/AN/AN/AN/A7/29/2024 (Estimated)
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/A

Latest SXTC, UMRX, GHSI, SEOVF, and KZIA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A$0.33+$0.33$0.33N/A$21.56 million
3/18/2024Q1 2024
Sernova Corp. stock logo
SEOVF
Sernova
N/A-$0.02-$0.02-$0.02N/AN/A
1/29/2024Q4 2023
Sernova Corp. stock logo
SEOVF
Sernova
N/A-$0.03-$0.03-$0.03N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/A
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
N/AN/AN/AN/AN/A
Sernova Corp. stock logo
SEOVF
Sernova
N/AN/AN/AN/AN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
9.01
6.98
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
N/A
0.71
N/A
Sernova Corp. stock logo
SEOVF
Sernova
0.14
1.20
1.20
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
0.02
1.47
1.41
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.18
2.90
2.90

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
91.28 million1.27 millionNot Optionable
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
2,02116.34 million16.18 millionOptionable
Sernova Corp. stock logo
SEOVF
Sernova
N/A303.41 millionN/ANot Optionable
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
78460,000439,000Not Optionable
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
7242.47 millionN/ANot Optionable

SXTC, UMRX, GHSI, SEOVF, and KZIA Headlines

SourceHeadline
Cogent Biosciences IncCogent Biosciences Inc
money.usnews.com - April 24 at 4:34 AM
Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)
markets.businessinsider.com - February 26 at 5:33 PM
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)
markets.businessinsider.com - February 26 at 8:53 AM
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
markets.businessinsider.com - February 26 at 8:53 AM
Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside PotentialBuy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potential
markets.businessinsider.com - February 15 at 8:43 AM
Cogent Biosciences Stock Soars After $225M Private PlacementCogent Biosciences Stock Soars After $225M Private Placement
marketwatch.com - February 14 at 10:02 AM
Cogent Biosciences announces oversubscribed $225M private placementCogent Biosciences announces oversubscribed $225M private placement
msn.com - February 14 at 10:02 AM
Buy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug ProspectsBuy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospects
markets.businessinsider.com - February 9 at 2:23 AM
Citi starts Cogent Biosciences at buy, cites GI tumor drug potentialCiti starts Cogent Biosciences at buy, cites GI tumor drug potential
msn.com - February 8 at 4:22 PM
Buy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT TrialBuy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trial
markets.businessinsider.com - December 15 at 7:55 PM
Maintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for BezuclastinibMaintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinib
markets.businessinsider.com - December 13 at 5:33 PM
Dow Surges 100 Points; Cogent Biosciences Shares PlungeDow Surges 100 Points; Cogent Biosciences Shares Plunge
markets.businessinsider.com - December 11 at 12:21 PM
Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis TreatmentCogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment
markets.businessinsider.com - December 11 at 12:21 PM
Cogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic MastocytosisCogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosis
markets.businessinsider.com - December 11 at 10:08 AM
Cogent slumps after mid-stage data for rare disorder therapyCogent slumps after mid-stage data for rare disorder therapy
msn.com - December 11 at 10:08 AM
Potential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced SharesPotential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Shares
markets.businessinsider.com - November 21 at 9:11 AM
Promising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent BiosciencesPromising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciences
markets.businessinsider.com - November 14 at 8:40 AM
Promising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent BiosciencesPromising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciences
markets.businessinsider.com - November 4 at 5:21 PM
Promising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy RatingPromising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Rating
markets.businessinsider.com - October 28 at 7:55 AM
Analyst Expectations for Cogent Biosciencess FutureAnalyst Expectations for Cogent Biosciences's Future
benzinga.com - August 30 at 8:53 AM
Cogent Biosciences Is Beginning To Differentiate Its KIT InhibitorCogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor
msn.com - August 15 at 5:40 PM
LifeSci Capital Remains a Buy on Cogent Biosciences (COGT)LifeSci Capital Remains a Buy on Cogent Biosciences (COGT)
markets.businessinsider.com - August 8 at 3:59 PM
Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?
msn.com - July 11 at 1:47 PM
Cogent Biosciences Shares Rise on Fairmount Funds Managements Stake AcquisitionCogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisition
marketwatch.com - June 13 at 11:04 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Guardion Health Sciences logo

Guardion Health Sciences

NASDAQ:GHSI
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported nutrition, medical foods, and dietary supplements in North America and Europe, and Internationally. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
Kazia Therapeutics logo

Kazia Therapeutics

NASDAQ:KZIA
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.
Sernova logo

Sernova

OTCMKTS:SEOVF
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
China SXT Pharmaceuticals logo

China SXT Pharmaceuticals

NASDAQ:SXTC
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
Cogent Biosciences logo

Cogent Biosciences

NASDAQ:UMRX
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.